Compare
Ultragenyx Pharmaceutical Inc. vs Kiniksa Pharmaceuticals International, plc vs Supernus Pharmaceuticals, Inc. vs Pacira BioSciences, Inc.
| Latest fiscal year | Ultragenyx Pharmaceutical Inc. RARE | Kiniksa Pharmaceuticals International, plc KNSA | Supernus Pharmaceuticals, Inc. SUPN | Pacira BioSciences, Inc. PCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $673.00M | $677.56M | $718.95M | $726.41M |
| Revenue growth (YoY) | +20.2% | +60.1% | +8.6% | +3.6% |
| Gross margin | n/a | 88.5% (computed) | 89.6% (computed) | 79.4% (computed) |
| Operating margin | -79.5% | 11.4% | -8.7% | 2.6% |
| Net margin | -85.4% | 8.7% | -5.4% | 1.0% |
| Net income | -$575.00M | $59.01M | -$38.55M | $7.03M |
| EPS (Diluted) | -$5.83 | $0.75 | -$0.68 | $0.16 |
| Operating cash flow | -$466.00M | $137.99M | $47.33M | $151.99M |
| Free cash flow | -$472.00M | $136.42M | $45.99M | $136.66M |
| Cash & equivalents | $421.00M | $165.60M | $128.45M | $158.54M |
| Total assets | $1.53B | $763.63M | $1.45B | $1.26B |
| Total liabilities | $1.60B | $196.03M | $390.93M | $571.81M |
| Shareholders' equity | -$80.00M | $567.61M | $1.06B | $693.11M |
| Return on year-end equity | n/a | 10.4% | -3.6% | 1.0% |
| Shares outstanding | 96.60M | n/a | 57.46M | 41.12M |
Revenue, most recent five fiscal years
| Fiscal year | Ultragenyx Pharmaceutical Inc. | Kiniksa Pharmaceuticals International, plc | Supernus Pharmaceuticals, Inc. | Pacira BioSciences, Inc. |
|---|---|---|---|---|
| Latest | $673.00M Ended 2025-12-31 | $677.56M Ended 2025-12-31 | $718.95M Ended 2025-12-31 | $726.41M Ended 2025-12-31 |
| 1 year earlier | $560.00M Ended 2024-12-31 | $423.24M Ended 2024-12-31 | $661.82M Ended 2024-12-31 | $700.97M Ended 2024-12-31 |
| 2 years earlier | $434.00M Ended 2023-12-31 | $270.26M Ended 2023-12-31 | $607.52M Ended 2023-12-31 | $674.98M Ended 2023-12-31 |
| 3 years earlier | $363.33M Ended 2022-12-31 | $220.18M Ended 2022-12-31 | $667.24M Ended 2022-12-31 | $666.82M Ended 2022-12-31 |
| 4 years earlier | $351.41M Ended 2021-12-31 | $38.54M Ended 2021-12-31 | $579.77M Ended 2021-12-31 | $541.53M Ended 2021-12-31 |